NurExone’s Exosomes Show Stronger Healing Potential Than Industry Standard
NurExone Biologic (OTCQB: NRXBF) announced that an independent study by TAmiRNA laboratory revealed their exosomes significantly outperformed commercial industry standards in key healing capabilities. The company's exosomes demonstrated approximately 1.8x higher neurological potential, 2x higher tissue-regeneration and wound-healing signals, and nearly double the anti-inflammatory activity compared to benchmark products.
The analysis, conducted on exosomes produced from NurExone's proprietary master cell bank, validates the company's core technology for therapeutic nerve repair and aesthetic applications. The exosomes will be manufactured by NurExone's U.S. subsidiary, ExoTOP Inc., using their patent-pending 3D production process.
NurExone Biologic (OTCQB: NRXBF) ha annunciato che uno studio indipendente del laboratorio TAmiRNA ha rilevato che i suoi esosomi hanno superato nettamente gli standard commerciali del settore nelle principali capacità di guarigione. Gli esosomi dell'azienda hanno mostrato un potenziale neurologico circa 1,8 volte superiore, segnali di rigenerazione tissutale e di cicatrizzazione 2 volte più forti e quasi il doppio dell'attività anti-infiammatoria rispetto ai prodotti di riferimento.
L'analisi, condotta su esosomi prodotti dal banco cellulare master proprietario di NurExone, convalida la tecnologia centrale dell'azienda per la riparazione terapeutica dei nervi e le applicazioni estetiche. Gli esosomi saranno prodotti dalla controllata statunitense ExoTOP Inc. di NurExone, utilizzando il loro processo produttivo 3D in attesa di brevetto.
NurExone Biologic (OTCQB: NRXBF) anunció que un estudio independiente del laboratorio TAmiRNA reveló que sus exosomas superaron significativamente los estándares comerciales de la industria en capacidades clave de curación. Los exosomas de la compañía demostraron un potencial neurológico aproximadamente 1,8 veces mayor, señales de regeneración tisular y cicatrización 2 veces superiores y casi el doble de actividad antiinflamatoria en comparación con los productos de referencia.
El análisis, realizado sobre exosomas producidos a partir del banco maestro de células de propiedad de NurExone, valida la tecnología central de la compañía para la reparación terapéutica de nervios y las aplicaciones estéticas. Los exosomas serán fabricados por la filial estadounidense ExoTOP Inc. de NurExone, utilizando su proceso de producción 3D pendiente de patente.
NurExone Biologic (OTCQB: NRXBF)는 TAmiRNA 연구소의 독립 연구에서 자사 엑소좀이 업계의 상용 표준을 주요 치유 능력 면에서 크게 능가한 것으로 나타났다고 발표했습니다. 회사의 엑소좀은 신경 관련 잠재력이 약 1.8배 높았고, 조직 재생 및 상처 치유 신호는 2배 더 강했으며 항염증 활성은 거의 두 배에 달했습니다(기준 제품 대비).
이 분석은 NurExone의 독점 마스터 세포 은행에서 생산된 엑소좀을 대상으로 수행되었으며, 치료용 신경 복구와 미용 적용을 위한 회사의 핵심 기술을 검증합니다. 엑소좀은 미국 자회사 ExoTOP Inc.에서 특허 출원 중인 3D 생산 공정을 사용해 제조될 예정입니다.
NurExone Biologic (OTCQB: NRXBF) a annoncé qu'une étude indépendante du laboratoire TAmiRNA a révélé que leurs exosomes dépassaient nettement les standards commerciaux du secteur en matière de capacités clés de guérison. Les exosomes de la société ont démontré un potentiel neurologique d'environ 1,8 fois supérieur, des signaux de régénération tissulaire et de cicatrisation 2 fois plus élevés et une activité anti‑inflammatoire presque doublée par rapport aux produits de référence.
L'analyse, réalisée sur des exosomes produits à partir de la banque cellulaire maîtresse propriétaire de NurExone, confirme la technologie centrale de la société pour la réparation thérapeutique des nerfs et les applications esthétiques. Les exosomes seront fabriqués par la filiale américaine ExoTOP Inc. de NurExone, en utilisant leur procédé de production 3D en instance de brevet.
NurExone Biologic (OTCQB: NRXBF) gab bekannt, dass eine unabhängige Studie des TAmiRNA-Labors ergab, dass ihre Exosome die kommerziellen Industriestandards in wichtigen Heilungsfunktionen deutlich übertrafen. Die Exosome des Unternehmens zeigten ein etwa 1,8‑fach höheres neurologisches Potenzial, 2‑fach stärkere Signale für Geweberegeneration und Wundheilung und nahezu doppelt so viel anti‑entzündliche Aktivität im Vergleich zu Referenzprodukten.
Die Analyse, durchgeführt an Exosomen, die aus dem firmeneigenen Master‑Zellbestand von NurExone produziert wurden, bestätigt die Kerntechnologie des Unternehmens für therapeutische Nervenreparatur und ästhetische Anwendungen. Die Exosome werden von der US‑Tochter ExoTOP Inc. von NurExone mittels ihres zum Patent angemeldeten 3D‑Produktionsverfahrens hergestellt.
- Independent study confirms superior performance versus industry benchmark across all healing pathways
- Exosomes show 1.8x higher neurological potential and 2x higher tissue-regeneration capability
- Patent-pending 3D production process ensures reproducible high-performance exosomes
- Technology validated for both therapeutic and aesthetic applications
- Production scaling and commercialization still pending
- Revenue generation from ExoTOP subsidiary yet to materialize
Independent Study and Bioanalysis Suggests More Effective Nerve Repair and Faster Wound Healing
TORONTO and HAIFA, Israel, Aug. 08, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) today announced that an independent study showed that exosomes produced by NurExone outperformed a recognized commercial industry standard in areas that strongly support key healing tasks including nerve repair, wound repair, calming the immune system and rebuilding tissue. This first independent analysis highlighted the broad potential of NurExone’s exosomes for both therapeutic and aesthetics markets.
“This data confirms that the naïve exosomes that will be manufactured by our U.S. subsidiary, ExoTOP Inc. (“ExoTOP”), will carry a strong regenerative and therapeutic punch. Delivering more than twice the wound-healing signals than the industry benchmark suggests applications in aesthetic skin rejuvenation, wound care and orthopedic tissue repair”, said Jacob Licht, Chief Executive Officer of ExoTOP. “As we scale production in the United States with our patent-pending 3D production process, ExoTOP is expected to generate multiple revenue streams and provide high-performance exosomes to partners across regenerative medicine.”
“Our exosomes carry complex cargo with diverse therapeutic potential, simultaneously being effective in neuroprotection and reduction in inflammation,” said Dr. Tali Kizhner, Director of R&D of NurExone Biologic. “This combination is especially powerful in the nervous system, where inflammation usually prevents healing. The benchmarking analysis confirms that our exosomes naturally carry a significant amount of the molecular signals needed to create the conditions required for meaningful nerve regeneration.”
TAmiRNA, an ISO 13485‑certified molecular‑diagnostics laboratory, performed a comprehensive analysis of the EV microRNA cargo of NurExone’s exosomes and compared the results with benchmark exosomes from a commercial reference source. Based on TAmiRNA’s data, bioinformatic analyses showed that NurExone’s exosomes are enriched with microRNAs that support key healing tasks.
Importantly, these exosomes were produced from NurExone’s proprietary master cell bank, whose cells are maintained under rigorously controlled environment ensuring that every production batch delivers high-performance exosomes. This reproducibility is essential for clinical translation and future patient use.
Figure 1 suggests that NurExone’s naïve exosomes outperform the commercial reference across every pathway assessed: they exhibit ≈1.8-fold higher neurological potential, nearly double the anti-inflammatory activity, and a full two-fold increase in both tissue-regeneration and wound-healing signals. This multi-modal, high-potency profile positions the exosomes as a versatile platform for therapeutic nerve repair as well as for aesthetic regenerative and longevity applications.
The results provide strong, third-party validation of NurExone’s core technology and highlight its potential across a broad range of regenerative-medicine applications.
About TAmiRNA GmbH
Vienna‑based TAmiRNA is an ISO 13485‑certified molecular‑diagnostics laboratory whose CE‑marked biomarker kits and miND® small‑RNA sequencing platform provide industry‑leading, ISEV‑compliant exosome analytics. Its extensive extracellular‑vesicle reference database and bench‑to‑algorithm workflow deliver regulatory‑grade, reproducible insights for precision‑medicine programs.
About NurExone
NurExone Biologic Inc. is a TSX Venture Exchange (“TSXV”), OTCQB, and Frankfurt-listed biotech company focused on developing regenerative exosome-based therapies for central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve injury, both multi-billion-dollar marketsi . Regulatory milestones, including obtaining the Orphan Drug Designation, facilitates the roadmap towards clinical trials in the U.S. and Europe. Commercially, the Company is expected to offer solutions to companies interested in quality exosomes and minimally invasive targeted delivery systems for other indications. NurExone has established Exo-Top Inc., a U.S. subsidiary, to anchor its North American activity and growth strategy.
For additional information and a brief interview, please watch Who is NurExone?, visit www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube.
For more information, please contact:
Dr. Lior Shaltiel
Chief Executive Officer and Director
Phone: +972-52-4803034
Email: info@nurexone.com
Dr. Eva Reuter
Investor Relations – Germany
Phone: +49-69-1532-5857
Email: e.reuter@dr-reuter.eu
Allele Capital Partners
Investor Relations – U.S.
Phone: +1 978-857-5075
Email: aeriksen@allelecapital.com
FORWARD-LOOKING STATEMENTS
This press release contains certain “forward-looking statements” that reflect the Company’s current expectations and projections about its future results. Wherever possible, words such as “may”, “will”, “should”, “could”, “expect”, “plan”, “intend”, “anticipate”, “believe”, “estimate”, “predict” or “potential” or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements relating to: the broad potential of the Company’s exosomes for both therapeutic and aesthetics markets; naïve exosomes manufactured by ExoTOP carrying a strong regenerative and therapeutic punch; the Company’s expectation that ExoTOP will generate multiple revenue streams and provide high-performance exosomes to partners across regenerative medicine; the reproducibility of the Company’s exosomes being essential for clinical translation and future patient use; third party data highlighting the potential of the Company’s core technology across a range of regenerative-medicine applications; and the NurExone platform technology offering novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications, including recovery of optic nerve function and overall visual health.
These statements reflect management’s current beliefs and are based on information currently available to management as at the date hereof. In developing the forward-looking statements in this press release, we have applied several material assumptions, including: the Company’s exosomes will have versatile applications supported by evidence displaying their effectiveness in regenerative medicine and aesthetics; the exosomes produced by ExoTOP are capable of delivering therapeutic effects; commercial scalability, market demand, and competitive advantage of ExoTOP’s exosomes; the Company’s exosomes will be therapeutically applied across various clinical trials; the Company’s manufacturing process will consistently produce exosomes to a standard sufficient for regulatory approval and clinical reliability; the Company’s exosomes will be effectively used in regenerative frameworks targeting nerve tissue as well as skin and aesthetics; the Company having credible external validation and supportive data to substantiate the potential of its technology; and the NurExone platform technology has the ability to offer novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications, including recovery of optic nerve function and overall visual health
Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These risks and uncertainties include, but are not limited to risks related to: slow market adoption; unanticipated safety concerns from novel clinical uses; regulatory and manufacturing compliance roadblocks the Company’s early stage of development; lack of revenues to date; the inherent uncertainty of preclinical drug development, including the risk that product candidates may not advance to clinical trials or receive regulatory approval; the possibility that results from preclinical studies and early-stage trials may not predict later outcomes; the uncertain timing, cost, and outcome of preclinical and clinical development activities; risks related to the clinical trial process, including potential delays or failure to achieve effective trial design or positive results; the inability to obtain or maintain required regulatory approvals; limited market acceptance of the Company’s products, even if approved; the potential emergence of competing therapies that are safer, more effective, or more affordable; rapid technological change that may impact the relevance of the Company’s technologies; the Company’s dependence on key personnel and strategic partners; the inability to obtain adequate financing; risks related to the Company’s ability to protect its intellectual property; the possibility that the Company’s technologies, including its exosome-based platforms, may not achieve their intended therapeutic impact; the inability to produce or scale exosome-based products for clinical use; limited adoption in regenerative medicine or cell therapy applications; lack of growing clinical demand in targeted indications such as spinal cord injury, optic nerve repair, or other therapeutic areas; failure to meet planned development milestones or achieve commercial breakthroughs; the Company will not initiate additional studies to explore alternative dosing regimens; the Company will not advance the optimization of ExoPTEN’s manufacturing processes and analytical methods; the NurExone platform technology not offering novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications, including recovery of optic nerve function and overall visual health; and the risks discussed under the heading “Risk Factors” on pages 44 to 51 of the Company’s Annual Information Form dated August 27, 2024, a copy of which is available under the Company’s SEDAR+ profile at www.sedarplus.ca. These factors should be considered carefully, and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
i Spinal cord injury, Glaucoma
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/adb4c1ac-d77e-4955-9ddf-39f41f799d4b
FAQ
What were the key findings of NurExone's (NRXBF) independent study in 2025?
How does NurExone's exosome technology compare to industry standards?
What is the potential market application for NurExone's (NRXBF) exosome technology?
Who conducted the analysis of NurExone's exosome technology?
How does NurExone ensure consistent exosome production quality?
